CS
ADPT icon

Comerica Securities’s Adaptive Biotechnologies ADPT Stock Holding History

Comerica Securities’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-67
Closed -$512 – 487
2022
Q4 		$512 Buy
+67
New +$521 ﹤0.01% 1418

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Comerica Securities's ADPT Position: Q1 2023 in Review

Comerica Securities sold out of Adaptive Biotechnologies (ADPT) in Q1 2023, closing a stake of 67 shares — an estimated $512 sold.

Comerica Securities first reported a position in ADPT in Q4 2022 and held it in 1 quarter. The position peaked at $512 in Q4 2022. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

  • Comerica Securities reported no remaining Adaptive Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Comerica Securities sold 67 Adaptive Biotechnologies shares in Q1 2023, an estimated $512.
  • Comerica Securities first reported a position in Adaptive Biotechnologies in Q4 2022 and held it in 1 quarter.
  • Comerica Securities's Adaptive Biotechnologies position peaked at $512 in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.